Jun 11, 2020
Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise's European Subsidiary, UPE
May 22, 2020
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020
Mar 16, 2020
Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
Mar 05, 2020
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020
Feb 04, 2020
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
Jan 03, 2020
Global Recombinant Cell Culture Supplements Markets, 2019-2029: Rising Demand for Monoclonal Antibodies and Stem Cell Research
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Oct 29, 2019
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019
Jan 22, 2019
DNA Vaccine Market is Anticipated to Rise at a Staggering CAGR During the Forecast Period: Radiant Insights, Inc.
Sep 17, 2018
Global DNA Vaccine Market Outlook 2022
Jul 25, 2018
SeraCare Announces the Expansion of Their Proprietary AccuPlex(TM) Technology Product Portfolio with the Launch of the AccuSpan(TM) HCV RNA Linearity Panel
Jan 16, 2018
CollPlant Appoints David Tsur as Chairman of the Board
Nov 15, 2017
A Non-Animal Sourced Recombinant Alternative to Bovine Trypsin
Sep 28, 2017
$844.6 Bn Recombinant DNA Technology Market Analysis to 2025 - Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals - Research and Markets
Sep 07, 2017
Recombinant DNA Technology Market Worth $844.6 Billion by 2025: Grand View Research, Inc.